These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31035765)

  • 21. Common gastrointestinal symptoms: risks of long-term proton pump inhibitor therapy.
    Fashner J; Gitu AC
    FP Essent; 2013 Oct; 413():29-39. PubMed ID: 24124705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overuse of proton pump inhibitors.
    Ksiądzyna D; Szeląg A; Paradowski L
    Pol Arch Med Wewn; 2015; 125(4):289-98. PubMed ID: 25790817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [What is the REAL long-term risk of proton pump inhibitors?].
    Ribiere S; Guillaumot MA; Barré A; Abou Ali E; Barret M; Chaussade S; Coriat R
    Presse Med; 2019 May; 48(5):503-510. PubMed ID: 30926204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant use of capecitabine and proton pump inhibitors - Is it safe?
    Cheng V; Lemos M; Hunter N; Badry N; Lemos J
    J Oncol Pharm Pract; 2019 Oct; 25(7):1705-1711. PubMed ID: 31081468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton pump inhibitor therapy and potential long-term harm.
    Corleto VD; Festa S; Di Giulio E; Annibale B
    Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):3-8. PubMed ID: 24310148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Loneliness of Patients in the Pre-Terminal and Terminal Stages of Cancer, the Social Dimension of Dying.
    Bencová V
    Klin Onkol; 2019; 32(3):220-223. PubMed ID: 31216856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary Tract and Gynecologic Malignancies.
    Špaček J; Petera J; Broďák M; Práznovec I; Špaček J
    Klin Onkol; 2018; 31(6):414-420. PubMed ID: 31035766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton pump inhibitors: Risks of long-term use.
    Eusebi LH; Rabitti S; Artesiani ML; Gelli D; Montagnani M; Zagari RM; Bazzoli F
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1295-1302. PubMed ID: 28092694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?
    Budha NR; Frymoyer A; Smelick GS; Jin JY; Yago MR; Dresser MJ; Holden SN; Benet LZ; Ware JA
    Clin Pharmacol Ther; 2012 Aug; 92(2):203-13. PubMed ID: 22739140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study.
    Ergun Y; Yildirim Ozdemir N; Toptas S; Kurtipek A; Eren T; Yazici O; Sendur MA; Akinci B; Ucar G; Oksuzoglu B; Uncu D
    J BUON; 2019; 24(4):1719-1726. PubMed ID: 31646831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].
    Maléth J; Hegyi P
    Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
    Obermannova R
    Klin Onkol; 2017; 30(Supplementum3):50-54. PubMed ID: 29239193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested case-control in a retrospective cohort study.
    Ramírez E; Cabañas R; Laserna LS; Fiandor A; Tong H; Prior N; Calderón O; Medrano N; Bobolea I; Frías J; Quirce S
    Clin Exp Allergy; 2013 Mar; 43(3):344-52. PubMed ID: 23414543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Gastrointestinal Flora in the Treatment of Cancer with Immune Checkpoint Inhibitors.
    Mendoza L
    Klin Onkol; 2018; 31(6):465-467. PubMed ID: 30545227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
    Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration.
    Raoul JL; Hansten PD
    Cancer Treat Rev; 2024 Sep; 129():102794. PubMed ID: 38968741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repositioning of proton pump inhibitors in cancer therapy.
    Lu ZN; Tian B; Guo XL
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton pump inhibitors--uncommon adverse effects.
    Oh S
    Aust Fam Physician; 2011 Sep; 40(9):705-8. PubMed ID: 21894279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Lalani AA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):724-732. PubMed ID: 28645482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controversial link between proton pump inhibitors and anticancer agents: review of the literature.
    Meriggi F
    Tumori; 2022 Jun; 108(3):204-212. PubMed ID: 34159850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.